Marshall Wace North America’s Pacira BioSciences PCRX Stock Holding History

Marshall Wace North America’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,367	Closed	-$236K	–	1687
2021 Q1	$236K	Sell	3,367 -6,336	-65%	-$453K	﹤0.01%	1376
2020 Q4	$582K	Buy	+9,703	New	+$568K	﹤0.01%	1053
2020 Q2	–	Sell	-24,752	Closed	-$830K	–	1392
2020 Q1	$830K	Sell	24,752 -71,773	-74%	-$2.98M	0.01%	645
2019 Q4	$4.37M	Buy	96,525 +25,529	+36%	+$1.08M	0.02%	413
2019 Q3	$2.7M	Buy	+70,996	New	+$2.83M	0.02%	480
2019 Q2	–	Sell	-84,624	Closed	-$3.22M	–	1500
2019 Q1	$3.22M	Buy	+84,624	New	+$3.3M	0.02%	399
2018 Q3	–	Sell	-32,571	Closed	-$1.04M	–	1258
2018 Q2	$1.04M	Sell	32,571 -36,747	-53%	-$1.27M	0.01%	919
2018 Q1	$2.16M	Sell	69,318 -2,280	-3%	-$81.2K	0.01%	796
2017 Q4	$3.27M	Buy	71,598 +56,623	+378%	+$2.24M	0.02%	696
2017 Q3	$569K	Sell	14,975 -13,239	-47%	-$533K	﹤0.01%	1049
2017 Q2	$1.35M	Buy	+28,214	New	+$1.31M	0.01%	841

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Marshall Wace North America's PCRX Position: Q2 2021 in Review

Marshall Wace North America sold out of Pacira BioSciences (PCRX) in Q2 2021, closing a stake of 3,367 shares — an estimated $236K sold.

Marshall Wace North America first reported a position in PCRX in Q2 2017 and held it in 11 quarters. The position peaked at $4.37M in Q4 2019. 262 funds tracked by Wall St. Rank hold PCRX as of Q2 2021.

Marshall Wace North America reported no remaining Pacira BioSciences position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 3,367 Pacira BioSciences shares in Q2 2021, an estimated $236K.
Marshall Wace North America first reported a position in Pacira BioSciences in Q2 2017 and held it in 11 quarters.
Marshall Wace North America's Pacira BioSciences position peaked at $4.37M in Q4 2019.
262 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.